Lymphoma

Lymphoma is a cancer of a part of the immune system called the lymphatic system. There are many types of lymphoma. One type is Hodgkin disease, and the other types are called non-Hodgkin lymphoma.

Programs + Services


Hematologic Malignancies Program

Tufts Medical Center's Hematologic Malignancies Program in Boston uses the latest techniques to pinpoint your cancer type and provide you with the most effective treatment.
More information about programs and services

Doctors + Care Team

Raymond L. Comenzo, MD

Raymond L. Comenzo, MD

Loading ...

Accepting New Patients

Virtual Appointments Available

Title(s): Director, Transfusion Services; Director, John C. Davis Myeloma and Amyloid Program; Professor, Tufts University School of Medicine
Department(s): Medicine, Pathology and Laboratory Medicine, Hematology/Oncology
Appt. Phone: 617-636-6454
Fax #: 617-636-3175

Myeloma, amyloidosis, stem cell transplant, transfusion medicine

View Full Profile for Raymond L. Comenzo, MD

Andreas K. Klein, MD

Andreas K. Klein, MD

Loading ...

Accepting New Patients

Virtual Appointments Available

Title(s): Associate Chief, Division of Hematology Oncology; Director, Hematologic Malignancies Program; Director, Bone Marrow and Hematopoietic Cell Transplant Program; Regulatory Affairs Director, CTSI; Associate Professor, Tufts University School of Medicine
Department(s): Medicine, Hematology/Oncology
Appt. Phone: 617-636-6227
Fax #: 617-636-8538

Lymphoma, myeloma, bone marrow transplantation (BMT), immune reconstitution after BMT

View Full Profile for Andreas K. Klein, MD

Susan K. Parsons, MD, MRP

Susan K. Parsons, MD, MRP

Accepting New Patients

Title(s): Founding Director, Reid R. Sacco Adolescent and Young Adult Program for Cancer and Hereditary Blood Diseases; Director, The Center for Health Solutions at the Institute for Clinical Research and Health Policy Studies; Professor, Tufts University School of Medicine
Department(s): Pediatrics, Cancer Center, Medicine, Pediatric Hematology/Oncology, Hematology/Oncology
Appt. Phone: 617-636-5168
Fax #: 617-636-6280

Pediatric bone marrow transplantation, long-term quality of life following transplantation, supportive medical and emotional care for patients and families

View Full Profile for Susan K. Parsons, MD, MRP

Monika Pilichowska, MD, PhD

Monika Pilichowska, MD, PhD

Title(s): Director, Clinical Hematology and Hematopathology; Director, Hematopathology Fellowship Program; Associate Professor, Tufts University School of Medicine
Department(s): Pathology and Laboratory Medicine
Appt. Phone: 617-636-7216
Fax #: 617-636-7128

Hematology and hematopathology, flow cytometry, surgical pathology and cytology, renal pathology (medical renal disease)

View Full Profile for Monika Pilichowska, MD, PhD

Research + Clinical Trials


A First-in-Human, Multicenter, Open-label, Phase 1 Dose-Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TAB004 as Monotherapy and in Combination with Toripalimab in Subjects with Advanced Solid Malignancies including Lymphoma (TAB004-01).

The primary objective is to assess the safety and tolerability of TAB004 as monotherapy and in combination with toripalimab in subjects with selected advanced solid malignancies, including lymphoma, and to evaluate the recommended Phase 2 dose.
More information about research and clinical trials


A051902, A randomized phase II study of CHO(E)P vs CC-486- CHO(E)P vs duvelisib- CHO(E)P in previously untreated CD30 negative peripheral T-cell lymphomas

This phase II trial studies the effect of duvelisib or CC-486 and usual chemotherapy consisting of cyclophosphamide, doxorubicin, vincristine, etoposide, and prednisone in treating patients with peripheral T-cell lymphoma. Duvelisib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. 
More information about research and clinical trials


ANHL1931: A Randomized Phase 3 trial of Nivolumab in Combination with Chemo-immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-cell Lymphoma

This phase III trial compares the effects of nivolumab with chemo-immunotherapy versus chemo-immunotherapy alone in treating patients with newly diagnosed primary mediastinal B-cell lymphoma (PMBCL).

Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of cancer cells to grow and spread.

Treatment for PMBCL involves chemotherapy combined with an immunotherapy called rituximab.

Chemotherapy drugs work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.

Rituximab is a monoclonal antibody. It binds to a protein called CD20, which is found on B cells (a type of white blood cell) and some types of cancer cells. This may help the immune system kill cancer cells. Giving nivolumab with chemo-immunotherapy may help treat patients with PMBCL.


More information about research and clinical trials


A Multicenter, Open-label, Phase 2 Basket Study to Evaluate the Safety and Efficacy of MK-2140 as a Monotherapy and in Combination in Participants with Aggressive and Indolent B-cell Malignancies

The study will enroll approximately 380 participants with aggressive B-cell malignancies and indolent B-cell malignancies.
More information about research and clinical trials


M23-362, A Phase 2, Open-Label Trial to Evaluate Safety of Epcoritamab Monotherapy in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma Grade 1-3a when Administered in the Outpatient Setting

The purpose of this study is to assess the safety of epcoritamab in adult participants in relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL) or R/R follicular lymphoma (FL). Epcoritamab is an investigational drug being developed for the treatment of R/R DLBCL and R/R FL. Study doctors will assess participants in a monotherapy treatment arm of epcoritamab.
More information about research and clinical trials


S1925: Randomized, Phase III Study of Early Intervention with Venetoclax and Obinutuzumab Versus Delayed Therapy with Venetoclax and Obinutuzumab in Newly Diagnosed Asymptomatic High-Risk Patients with Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma (CLL/SLL): EVOLVE CLL/SLL Study

This phase III trial compares early treatment with venetoclax and obinutuzumab versus delayed treatment with venetoclax and obinutuzumab in patients with newly diagnosed high-risk chronic lymphocytic leukemia or small lymphocytic lymphoma. Venetoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors. It may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. Immunotherapy with monoclonal antibodies, such as obinutuzumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Starting treatment with the venetoclax and obinutuzumab early (before patients have symptoms) may have better outcomes for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma compared to starting treatment with the venetoclax and obinutuzumab after patients show symptoms.
More information about research and clinical trials